SOURCE: Avid Bioservices

Avid Bioservices

March 24, 2015 13:00 ET

Avid Bioservices Receives CMO Leadership Awards for Its Commitment to Innovation and Reliability

TUSTIN, CA--(Marketwired - Mar 24, 2015) - Avid Bioservices, Inc., the contract manufacturing subsidiary of Peregrine Pharmaceuticals, Inc., today announced that it has been recognized as a leader in two categories, Innovation and Reliability, at the annual Contract Manufacturing Organization (CMO) Leadership Awards. Awarded by the industry publication Life Science Leader and based on research conducted by industry intelligence agency, NiceInsight, these awards are based upon votes and nominations from the pharmaceutical and biopharmaceutical companies that utilize CMO services. These data help pharma and biopharma companies focus on CMO partners who are best suited to handle their projects and who are influencing the direction of the industry.

"Recognition by leaders in the CMO industry is a great honor as Avid continually strives to build the most comprehensive experience for our clients," said Steven King, president of Avid. "At Avid, our teams take great pride in helping to bring important biologics to the patients that need them the most and we see this recognition as a true testament to the dedication of our teams and their commitment to our clients. As our business grows, all of us at Avid will continue to seek constant improvements through the implementation of innovative approaches aimed at providing the highest level of value and quality for our clients and their patients."

For more information, please visit:

Avid is also participating in the following industry events, where it will highlight in case studies the biomanufacturing services surrounding some recent successes:

International Society for Pharmaceutical Engineering (ISPE) LA Chapter Event
Tuesday, March 24, 2015  
Avid Bioservices facility, Tustin, CA
For additional information on the ISPE Event, please visit:

IBC's Biopharmaceutical Development & Production Week Conference
March 30-April 2, 2015  
Hyatt Regency Resort & Spa, Huntington Beach, CA
Avid will present the following posters, which will be on display Wednesday, April 1st and Thursday, April 2nd:

  • "Generation of Host Cell Protein Assay Reagents for Development of a Process-Specific Host Cell Protein Assay"
    Presented by Dr. Jeanette Doerr, Sr. Scientist, Molecular Cell Biology

  • "Variability of Triton X-100 Impacts Product Solution Clarity During Solvent/Detergent Treatment"
    Presented by David Briggs, Ph.D., Associate Scientist, Manufacturing Science and Technology (MSAT)

  • "Reducing Residual DNA with No Impact on Critical Quality Attributes: A Case Study Using Modified Ceramic Hydroxyapatite (CHT) Conditions to Selectively Remove Host Cell DNA Contaminants"
    Presented by Payam Farahani, Associate Scientist, Process Sciences

Avid Bioservices will also host conference attendees in booth #114 in the exhibition hall from Monday, March 30th to Thursday, April 2nd.

For more information on IBC's Biopharmaceutical Development & Production Week Conference, please visit:

About Avid Bioservices

Avid Bioservices provides a comprehensive range of high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 20 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, final product filling, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (, which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at

Contact Information

  • For further information please contact:
    Chris Keenan
    Kelly Pisarev Lord
    (800) 987-8256